<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115254</url>
  </required_header>
  <id_info>
    <org_study_id>19-353</org_study_id>
    <nct_id>NCT04115254</nct_id>
  </id_info>
  <brief_title>Stereotactic Magnetic Resonance Guided Radiation Therapy</brief_title>
  <official_title>A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a master prospective Phase I-II trial evaluating feasibility and efficacy of&#xD;
      stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients&#xD;
      with cancer.&#xD;
&#xD;
        -  The phase 1 study will evaluate the feasibility and safety of delivering SMART in&#xD;
           patients with cancer.&#xD;
&#xD;
        -  Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and&#xD;
           improvement in patient reported outcome measures&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a feasibility study, which means it is the first-time investigators at&#xD;
      this institution are examining this type of MR-guided radiation to treat cancer.&#xD;
&#xD;
      The U.S. Food and Drug Administration (FDA) has approved this device as a treatment option&#xD;
      for cancer.&#xD;
&#xD;
      In this research study, the investigators are hoping to determine if adjusting radiation&#xD;
      treatments based on daily MRI has a feasible way to deliver radiation for participants with&#xD;
      pancreatic, lung or renal cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants will be assigned to one treatment arm only depending on their cancer type, and will be taken off study once treatment and follow up are complete.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery Success Rate for SMART across multiple tumors-Phase I</measure>
    <time_frame>1 year</time_frame>
    <description>Enrolling patients and delivering SMART on the MR Linac</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor visualization-Phase I</measure>
    <time_frame>1 Year</time_frame>
    <description>Assessing tumor using MR guidance before, during and after MR-guided treatment patient</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plan creation-Phase I</measure>
    <time_frame>1 Year</time_frame>
    <description>Generating adaptive plans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Improvement in Tumor Control-Phase II</measure>
    <time_frame>1 Year</time_frame>
    <description>Statistical power will be defined in each cohort individually and will be specific to each disease site tested.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Acute Toxicity-Phase I</measure>
    <time_frame>90 Days</time_frame>
    <description>Any related ≥ Grade 3 AE which is possibly, probably or definitely related to SMART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment-Phase 1</measure>
    <time_frame>90 Days</time_frame>
    <description>Duration of treatment with goal of &gt;80% of cases treated within 90 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment fractions-Phase1</measure>
    <time_frame>90 Days</time_frame>
    <description>Number of treatment fractions that would have resulted in unacceptably high dose (exceeding constraint) to an OAR without SMART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with long term toxicity-Phase II</measure>
    <time_frame>365 Days</time_frame>
    <description>assessing long-term (12 month) toxicity in patients receiving SMART</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Survival Rate-Phase II</measure>
    <time_frame>365 Days</time_frame>
    <description>Kaplan-Meier curve estimates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate-Phase II</measure>
    <time_frame>365</time_frame>
    <description>Kaplan-Meier curve estimates</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Adrenal Metastases</condition>
  <condition>Prostate Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Oligoprogressive Nodal Metastases</condition>
  <condition>Metachronous Nodal Metastases</condition>
  <condition>Synchronous Nodal Metastases</condition>
  <condition>Mesothelioma</condition>
  <condition>Spine Metastases</condition>
  <condition>Brain Metastases</condition>
  <condition>Borderline Resectable Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-ADRENAL METASTASES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-LIVER METASTASES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- METACHRONOUS OLIGOMETASTATIC NODES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- OLIGOPROGRESSIVE OLIGOMETASTATIC NODES/SOFT TISSUE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SYNCHRONOUS OLIGOMETASTATIC NODES/SOFT TISSUE METASTASES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE CANCER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BORDERLINE RESECTABLE PANCREAS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BRAIN METASTASIS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- MESOTHELIOMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE BOOST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PELVIC RE-IRRADIATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SPINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMART will be administered per each individual disease site standards</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MR-guided Linac</intervention_name>
    <description>Radiation will be delivered on an MR-guided Linear Accelerator</description>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BORDERLINE RESECTABLE PANCREAS</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- BRAIN METASTASIS</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- MESOTHELIOMA</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- METACHRONOUS OLIGOMETASTATIC NODES</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- OLIGOPROGRESSIVE OLIGOMETASTATIC NODES/SOFT TISSUE</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PELVIC RE-IRRADIATION</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE BOOST</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- PROSTATE CANCER</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SPINE</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION- SYNCHRONOUS OLIGOMETASTATIC NODES/SOFT TISSUE METASTASES</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-ADRENAL METASTASES</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-LIVER METASTASES</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Lung</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Pancreatic</arm_group_label>
    <arm_group_label>PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION-Renal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a confirmed malignancy requiring stereotactic body radiation&#xD;
             therapy. See specific disease site cohorts for more details.&#xD;
&#xD;
          -  Tumor size ≤ 7cm&#xD;
&#xD;
          -  Age 18 years of older.&#xD;
&#xD;
          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
          -  Specific eligibility requirements for each disease site with be covered in each&#xD;
             specific cohort.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specific exclusion requirements for each disease site with be covered in each specific&#xD;
             cohort&#xD;
&#xD;
          -  History of allergic reactions attributed to gadolinium-based IV contrast.&#xD;
&#xD;
             -- Note: If a patient will not receive contrast, this is not applicable&#xD;
&#xD;
          -  Pregnant women are excluded from this study.&#xD;
&#xD;
          -  Severe claustrophobia or anxiety&#xD;
&#xD;
          -  Participants who cannot undergo an MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Leeman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Leeman, MD</last_name>
    <phone>617-732-6452</phone>
    <email>JONATHANE_LEEMAN@DFCI.HARVARD.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Leeman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Leeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Leeman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Leeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jonathan Leeman, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>MRIdian Linear Accelerator</keyword>
  <keyword>Pancreas Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Renal Cancer</keyword>
  <keyword>Adrenal Metastases</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>Oligoprogressive</keyword>
  <keyword>Metachronous</keyword>
  <keyword>Synchronous</keyword>
  <keyword>Spine</keyword>
  <keyword>Prostate Boost</keyword>
  <keyword>Pelvic Re Irradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Dr. Jonathan Leeman (jonathane_leeman@dfci.harvard.edu). The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>BWH - Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

